Search Results - D. A. Napalkov

Refine Results
  1. 1

    Russian Trial ALGORITHM: Implementation of Combined Antihypertensive and Hypolipidemic Treatment for Clinical Efficacy Achievement in Routine Clinical Practice by D. A. Napalkov

    Published 2020-01-01

    Aim. To study the clinical outcomes (achievement of target blood pressure [BP]) and tolerability of antihypertensive and hypolipidemic therapy with fixed combinations of indapamide/perindopril, amlodipine/perindopril, amlodipine/indapamide/perindopril and rosuvastatin in patients with hypertension a...

    Full description

    Get full text
    Article
  2. 2

    THE SAFETY OF STATINS: WHAT A PHYSICIAN NEEDS TO KNOW by D. A. Napalkov

    Published 2015-09-01

    Various aspects of the safety of statins in clinical practice are discussed: hepatotoxicity, myopathy and rhabdomyolysis, the impact on the diabetes and cognitive dysfunction onset, renal function impairment.

    Get full text
    Article
  3. 3

    STROKE PREVENTION IN INTERNIST PRACTICE by D. A. Napalkov, A. V. Zhilenko

    Published 2016-01-01

    Stroke secondary prevention in internist practice is discussed in accordance with up to date guidelines. Modern pharmacotherapy includes antiaggregants or anticoagulants, statins, and antihypertensive drugs. The choice of drugs is mostly founded on the rules of evidence based medicine, which allow a...

    Full description

    Get full text
    Article
  4. 4

    MANAGEMENT OF PATIENT WITH ARTERIAL FIBRILLATION: WHAT`S NEW? by D. A. Napalkov, A. A. Sokolova

    Published 2016-12-01

    The literary review consists of two parts. The first takes into consideration the renewed European guidelines of 2016 for atrial fibrillation patients management. The accent is made on the renewed approaches for anticoagulation treatment regardless the gender, on new points in the risks of haemorrha...

    Full description

    Get full text
    Article
  5. 5

    Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy by D. A. Napalkov, A. A. Sokolova

    Published 2019-09-01

    The article discusses issues related to the prescription of anticoagulant therapy to elderly patients with atrial fibrillation (AF), especially those over 70 and 80 years of age. The relevance of the issue is primarily due to the prevalence of AF in this cohort of patients, and the second is due to...

    Full description

    Get full text
    Article
  6. 6
  7. 7

    The rational approach to selection of anticoagulation for stroke prevention in patients with atrial fibrillation of non-valvular etiology by D. A. Napalkov, A. A. Sokolova

    Published 2014-03-01

    The question of how to use most eff ectively and safely drugs from the group of oral anticoagulants for prevention of thromboembolic complications (TEC) in patients with atrial fi brillation (AF) non-valvular etiology is analyzed in this paper.

    Get full text
    Article
  8. 8

    Atrial Fibrillation: a Marker or Risk Factor for Stroke by B. A. Tatarsky, D. A. Napalkov

    Published 2023-03-01

    Atrial fibrillation (AF) is strongly associated with stroke risk, but an association by itself does not necessarily imply causation. The question remains whether AF is a risk factor for stroke and whether treatment that reduces the severity of AF will also reduce the burden of stroke. On the other h...

    Full description

    Get full text
    Article
  9. 9

    CARDIOPROTECTIVE AND NEPHROPROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR RAMIPRIL by D. A. Napalkov, E. N. Golovenko

    Published 2016-01-01

    There is grate interest to ACE inhibitors which have cardioprotective and neproprotective effects. Ramipril efficacy in ischemic heart disease prevention as well as ramipril positive effect on myocardium in adolescents is presented on the base of some trails. Ramipril ability to delay of diabetic an...

    Full description

    Get full text
    Article
  10. 10

    Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivolol by V. I. Makolkin, D. A. Napalkov

    Published 1970-01-01

    Beta-adrenoblockers, included in any cardiovascular disease treatment standard, became a key part of clinical practice only in late XX century. Nebivolol is a highly selective beta-1 -adrenoiblocker, modulating endothelial NO release and subsequent physiological vasodilatation. Nebivolol has multipl...

    Full description

    Get full text
    Article
  11. 11

    Optimal treatment strategies in comorbid patients with hypertension and dyslipidemia: the role of fixed-dose combinations by A. A. Sokolova, D. A. Napalkov

    Published 2023-12-01

    The publication reflects the modern strategy and potential of various fixed-dose combinations in comorbid patients with hypertension and lipid metabolism disorders. Based on guidelines and key randomized studies, algorithms for prescribing combination drugs are proposed depending on the clinical cha...

    Full description

    Get full text
    Article
  12. 12

    NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY by D. A. Napalkov, A. A. Sokolova

    Published 2015-09-01

    Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile of the new oral anticoagulants is significantly better than vitamin K antagonists profile, but requires con...

    Full description

    Get full text
    Article
  13. 13

    Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease by I. S. Daabul, A. A. Sokolova, D. A. Napalkov

    Published 2016-11-01

    Prevalence of atrial fibrillation (AF) in population is very high and continues to grow. According to the existing statistics its prevalence reaches about 2% so it is twice more, than it was considered in the last decade. Prevalence of AF among patients with chronic kidney disease (CKD) varies from...

    Full description

    Get full text
    Article
  14. 14

    COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS by V. A. Sulimov, D. A. Napalkov, A. A. Sokolova

    Published 2015-09-01

    Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed indirect comparisons.

    Get full text
    Article
  15. 15

    Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review by B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov

    Published 2019-11-01

    Direct oral anticoagulants (not vitamin K antagonists), unlike standard oral anticoagulants (e.g. warfarin), have a predictable manifestation of the anticoagulant effect and the possibility of using a fixed dose without the need for constant monitoring of the anticoagulant effect. The rapid onset an...

    Full description

    Get full text
    Article
  16. 16

    ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? by D. A. Napalkov, A. A. Sokolova, A. V. Rodionov

    Published 2016-05-01

    Up-to-date European approaches to the management of patients with atrial fibrillation (AF) after acute coronary syndrome and/or percutaneous coronary interventions are considered. Features of antithrombotic therapy in the early (hospital) and the delayed periods (up to 1 year after acute ischemic ev...

    Full description

    Get full text
    Article
  17. 17

    INTERRELATION BETWEEN PERSISTENT NECROSIS OF CARDIOMYOCYTES AND PROGNOSIS IN PATIENTS WITH CHRONIC HEART FAILURE by E. N. Golovenko, D. A. Napalkov, V. A. Sulimov

    Published 2016-01-01

    Background. Chronic heart failure (CHF) progression is accompanied by remodeling of muscular, collagen and vascular elements of myocardium. This can lead to increase in serum concentrations of myocardial lesion markers (cardiac troponin I (TrI) and myoglobin) which seem to correlate with poor progno...

    Full description

    Get full text
    Article
  18. 18

    Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants by A. D. Aga, A. A. Sokolova, D. A. Napalkov

    Published 2023-01-01

    Left ventricular thrombus (LVT) is a serious risk factor for systemic embolism development. Despite the evident danger of this condition, current guidelines describe management of patients with this potentially fatal complication very briefly. LVT can complicate myocardial infarction where its incid...

    Full description

    Get full text
    Article
  19. 19

    Metformin in metabolic syndrome treatment by V. I. Podzolkov, D. A. Napalkov, V. I. Makolkin

    Published 2005-06-01

    Aim. To compare the influence of standard and complex (including metformin) antihypertensive therapy on 24- hour blood pressure monitoring (BPM), biochemical and hormonal parameters in patients with metabolic syndrome (MS). Material and Methods. The study included 54 patients with MS: 34 males and 2...

    Full description

    Get full text
    Article
  20. 20

    The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality by B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov

    Published 2020-05-01

    The purpose of this review is to analyze the results of randomized clinical trials, meta-analyses of cohort and observational studies in real clinical practice on the influence of dabigatran etexilate on the risk of myocardial infarction in patients with atrial fibrillation. A pivotal RE-LY study on...

    Full description

    Get full text
    Article